Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 16,859 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: PCOS
Interventions: Dexamethasone, recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy, Long QT Syndrome, Congenital Heart Disease
Interventions: ICD lead implant, Thin leads; Device
Lead sponsor: Charles Berul; Other
Eligibility: 1 Year to 55 Years
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osgood-Schlatter Syndrome (OSS), Sinding-Larson and Johansson Syndrome (SLJ), Sever's Disease, Apophysitis
Interventions: Static Stretch, Active Elongation; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 8 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Nevirapine, Stavudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California • Providence, Rhode Island

Conditions: HIV Infections
Interventions: IBFT /HIV prevention, IBFT; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 15 Years to 20 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1)
Interventions: PAS-004 Tablets, PAS-004 Capsule; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cardiometabolic Syndrome, Physical Inactivity, Hypertension, Type 2 Diabetes, PreDiabetes, Obesity, Cardiovascular Diseases, Smoking, Sleep, Hyperlipidemias, Diet, Healthy, Blood Pressure
Interventions: Black Impact Intervention; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sleep Apnea, Obstructive
Interventions: Trazodone, Placebo; Drug
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis C, Hepatocellular Carcinoma
Interventions: Sofosbuvir, Ribavirin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: Prader-Willi Syndrome
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: UC-781 carbomer gel, 0.1% and 0.25%; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 21 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Atlanta, Georgia • Arlington, Virginia

Conditions: COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
Interventions: Not listed
Lead sponsor: Wilkes University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: romidepsin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Down Syndrome, Subclinical Hypothyroidism
Interventions: Levothyroxine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 20 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
Interventions: Duloxetine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Low Back Pain
Interventions: Caudal epidural injection, Percutaneous adhesiolysis; Procedure
Lead sponsor: Pain Management Center of Paducah; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: HIV Infection, Sexual Behavior, Health Behavior
Interventions: Self-acceptance based intervention, HIV/STI counseling and testing; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 608 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibromyalgia
Interventions: Paced Auditory Serial Addition task (PASAT); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Dunwoody, Georgia • Chicago, Illinois • Portland, Maine + 9 more

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Byteflies Remote patient monitoring solution (with reduced EEG); Device
Lead sponsor: Byteflies; Industry
Eligibility: 3 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Louisville, Kentucky • Austin, Texas • Tacoma, Washington

Conditions: Chemical Injury, Chemicals; Intoxication, Acute Respiratory Distress Syndrome, Distress Respiratory Syndrome, Medical Emergencies
Interventions: Clinical interventions performed in acute settings (contaminated environment), Protection (clinician and patient), Decontamination (clinician and patient); Procedure
Lead sponsor: St. Justine's Hospital; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Fanconi Anemia Complementation Group A
Interventions: RP-L102; Biological
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Stanford, California • Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome
Interventions: Mindfulness based Stress Reduction Training (MBSR); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

Pediatric Lead Extractability and Survival Evaluation (PLEASE)

Comparison of Three Treatments for Lower Extremity Apophysitis

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Preventing HIV/Aids in Drug Abusing Youth

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

Trazodone Dose Tolerance and APAP Adherence

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Botswana Study of UC-781 Vaginal Microbicide

Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain

Fostering Resilience to Psychosocial and HIV Risk in Indian MSM

Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS

The Medical Management in Patients Exposed to Weapons of Mass Destruction

Gene Therapy for Fanconi Anemia, Complementation Group A

Neuroimaging and Biomarkers in Chronic Visceral Pain